Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "Buy" rating for Anixa Biosciences with a target price of $10.00, suggesting a potential upside of 193.69% from its current stock price.
• Anixa Biosciences stock recently increased by 3.2% to $3.41, with a one-year range between $2.07 and $4.20.
• Recently, insiders have purchased a total of 35,000 shares worth $110,700, indicating confidence in the company's future.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report)'s stock had its "buy" rating reaffirmed by D. Boral Capital in a report issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. D. Boral Capital's price objective indicates a potential upside of 193.69% from the stock's current price.

Several other brokerages also recently commented on ANIX. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Thursday, September 11th. Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $9.00.

Anixa Biosciences Stock Up 3.2%

Anixa Biosciences stock traded up $0.11 during mid-day trading on Monday, reaching $3.41. 60,374 shares of the company's stock were exchanged, compared to its average volume of 107,394. The firm has a market capitalization of $112.08 million, a PE ratio of -9.68 and a beta of 0.58. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The business's fifty day simple moving average is $3.12 and its 200 day simple moving average is $2.98.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Wednesday, September 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, sell-side analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction on Thursday, July 31st. The shares were purchased at an average price of $3.08 per share, for a total transaction of $30,800.00. Following the transaction, the director directly owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. This represents a 1.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders purchased 35,000 shares of company stock worth $110,700. Corporate insiders own 25.30% of the company's stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds have recently added to or reduced their stakes in ANIX. Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter valued at $26,000. Jane Street Group LLC purchased a new position in shares of Anixa Biosciences in the 4th quarter valued at approximately $67,000. Private Advisor Group LLC purchased a new position in Anixa Biosciences during the first quarter valued at $35,000. Marshall Wace LLP bought a new stake in shares of Anixa Biosciences in the second quarter worth $39,000. Finally, Benjamin Edwards Inc. bought a new stake in Anixa Biosciences during the second quarter valued at about $37,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.